High concentrations of triglycerides are associated with diabetic kidney disease in new-onset type 2 diabetes in China: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study

Lei Gong PhD1,2,3,4 | Chuan Wang PhD1,2,3,4 | Guang Ning PhD5,6 | Weiqing Wang PhD5,6 | Gang Chen PhD7 | Qin Wan PhD8 | Guijun Qin PhD9 | Li Yan PhD10 | Guixia Wang PhD11 | Yingfen Qin PhD12 | Zuojie Luo PhD12 | Xulei Tang PhD13 | Yanan Huo PhD14 | Ruying Hu PhD15 | Zhen Ye PhD15 | Lixin Shi PhD16 | Zhengnan Gao PhD17 | Qing Su PhD18 | Yiming Mu PhD19 | Jiajun Zhao PhD20 | Lulu Chen PhD21 | Tianshu Zeng PhD21 | Xuefeng Yu PhD22 | Qiang Li PhD23 | Feixia Shen PhD24 | Yinfei Zhang PhD25 | Youmin Wang PhD26 | Huacong Deng PhD27 | Chao Liu PhD28 | Shengli Wu PhD29 | Tao Yang PhD30 | Yufang Bi PhD3 | Jieli Lu PhD5,6 | Mian Li PhD5,6 | Yu Xu PhD5,6 | Min Xu PhD5,6 | Tiange Wang PhD5,6 | Zhiyun Zhao PhD5,6 | Xinguo Hou PhD1,2,3,4 | Li Chen PhD1,2,3,4

1Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China
2Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, China
3Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, China
4Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Jinan, China
5Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China
8The Affiliated Hospital of Luzhou Medical College, Luzhou, China
9The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
10Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
11The First Hospital of Jilin University, Changchun, China
12The First Affiliated Hospital of Guangxi Medical University, Nanning, China
13The First Hospital of Lanzhou University, Lanzhou, China
14Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, China
15Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China

*Lei Gong and Chuan Wang contributed equally to this work.

Received: 12 March 2021 Revised: 2 July 2021 Accepted: 25 July 2021

© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Aims: The aims of this study were to evaluate the associations of metabolic abnormalities with incident diabetic kidney disease (DKD) and to explore whether dyslipidaemia, particularly high fasting triglyceride (TG), was associated with the development of DKD.

Methods: In total, 11,142 patients with new-onset type 2 diabetes with baseline estimated glomerular filtration rates (eGFR) ≥60 mL/min/1.73 m² were followed up during 2011-2016. Incident DKD was defined as eGFR <60 mL/min/1.73 m² at follow-up. Multiple logistic regression analysis was conducted to explore the relationship of metabolic abnormalities at baseline and at follow-up with risks of DKD. High TG was defined by TG ≥1.70 mmol/L. Low high-density lipoprotein cholesterol (HDL-c) was defined by HDL-c <1.0 mmol/L for men or <1.3 mmol/L for women.

Results: Participants who developed DKD had higher levels of waist circumference and systolic blood pressure, and lower levels of HDL-c at both baseline and follow-up visits. The DKD group also had higher levels of post-load plasma glucose and TG at follow-up. Multivariate logistic regression analysis revealed that both high TG at baseline [odds ratio (OR) = 1.37, p = .012] and high TG at follow-up (OR = 1.71, p < .001) were significantly associated with increased risks of DKD. Patients with high TG levels at both baseline and follow-up had higher risk of DKD compared with constantly normal TG (OR = 1.65, p < .001) after adjustment for covariates.

Conclusions: In a large population of patients with new-onset type 2 diabetes, a high TG level was an independent risk factor for the development of DKD. Tight TG control might delay the occurrence of DKD.

Keywords: diabetic kidney disease, new-onset type 2 diabetes, triglyceride
1 | INTRODUCTION

The prevalence of diabetes continues to increase significantly worldwide.\textsuperscript{1,2} About 20%-40% of patients with diabetes are complicated with diabetic kidney disease (DKD), which is the leading cause of chronic kidney disease and end-stage renal disease.\textsuperscript{3,4} It is important to note that DKD progresses even after strict control for risk factors such as blood glucose, blood pressure (BP) and body weight. Markers of diabetic kidney injury in patients with type 2 diabetes include uric acid, mean platelet volume/lymphocyte count ratio, neutrophil gelatinase-associated lipocalin and kidney injury molecule-1, etc.\textsuperscript{5-8} Continued surveillance and effective control are needed to reduce the burden of DKD, which prompts investigations into the factors related to the onset and progression of DKD.\textsuperscript{9,10}

Hypertriglyceridaemia is one of the most common clinical lipid abnormalities.\textsuperscript{11} Severe hypertriglyceridaemia significantly increases the risk of pancreatitis, and a moderate level of triglycerides (TGs) increases the risk of cardiovascular disease.\textsuperscript{12,13} In addition, we recently demonstrated that poor control of plasma TGs was associated with early decline of estimated glomerular filtration rates (eGFR) in new-onset type 2 diabetes.\textsuperscript{10}

Accumulation of lipids in the kidney may lead to glomerular damage through induction of oxidative stress or release of proinflammatory cytokines that lead to glomerulosclerosis and interstitial fibrosis.\textsuperscript{14,15} However, findings are controversial regarding the association between hypertriglyceridaemia and DKD. One study reported that lower high-density lipoprotein cholesterol (HDL-c) levels but not higher TG levels seem to be associated with the progression of DKD in men but not in women.\textsuperscript{16} Another study in Asians showed that among serum lipids, only HDL-c was associated with the progression of albuminuria.\textsuperscript{17} In contrast to these results, the UK Prospective Diabetes Study showed that TGs and low-density lipoprotein cholesterol (LDL-c) were reported to be independent risk factors for the progression of DKD.\textsuperscript{18} Therefore, varied ethnicities, gender and other population characteristics might result in different findings, and the impact of hypertriglyceridaemia on the kidney in patients with diabetes needs further investigation. In addition, previous studies were mostly cross-sectional. Therefore, using data from a large, nationwide, multicentre, prospective cohort of Chinese adults, we examined the associations of metabolic abnormalities, particularly dyslipidaemia, at baseline and at follow-up with the development of DKD in patients with new-onset type 2 diabetes.

2 | METHODS

2.1 | Study population

The China Cardiometabolic Disease and Cancer Cohort (4C) Study is a multicentre, nationwide, population-based prospective cohort study exploring the associations of metabolic factors with incident diabetes, cardiovascular events, cancer and all-cause mortality in Chinese individuals aged ≥40 years. The details of the 4C Study design have been described previously.\textsuperscript{19,20} During 2011-2012, participants underwent a comprehensive set of questionnaires, clinical measurements, oral glucose tolerance tests and laboratory examinations following a standard protocol at the baseline visit. During 2014-2016, participants were asked to come back and the examinations were repeated at the follow-up visit. At baseline, we defined 23,793 patients with new-onset type 2 diabetes based on the American Diabetes Association (ADA) diagnostic criteria.\textsuperscript{21} In addition, we excluded: (a) participants with eGFR <60 mL/min/1.73 m\textsuperscript{2} at baseline (n = 573); (b) participants with previously diagnosed hypertension including treated hypertension (n = 4126); (c) participants with previously diagnosed dyslipidaemia including treated dyslipidaemia (n = 152); (d) participants without eGFR levels at follow-up (n = 6724); and (e) participants with missing data on overweight/obesity, hypertension, glycaemic control and dyslipidaemia at baseline or at follow-up (n = 1076). Eventually, 11,142 participants were included for the current analysis and the median duration of follow-up was 3.1 years.

The study protocol and informed consent were approved by the Committee on Human Research at Ruijin Hospital affiliated to the Jiaotong University School of Medicine on 10 March 2011 (ethical approval number RUIJIN-2011-14). All participants provided written informed consent.

2.2 | Data collection and measurements

The methods of data collection and measurements have been described in detail in previous studies.\textsuperscript{19,20} Generally, standard questionnaires were used to collect demographic characteristics, medical history and family history, and lifestyle such as smoking, drinking and physical activity. Height, weight, waist circumference and BP were measured according to a standard protocol, and body mass index (BMI) was calculated as the weight in kilograms divided by height in meters squared. All participants underwent a 75-g oral glucose tolerance test after an overnight fast of at least 10 h. Fasting and 2 h post-load blood glucose (PBG) were measured locally with a glucose oxidase or hexokinase method. Fasting blood samples were centrifuged at study sites. Serum samples were aliquoted and frozen at −80°C within 2 h of collection and they were shipped in dry ice to the central laboratory in Shanghai accredited by the College of American Pathologists, where fasting serum TG, HDL-c, LDL-c and creatinine were measured by using an ARCHITECT c16200 autoanalyser (Abbott Laboratories, Abbott Park, IL, USA). Finger capillary whole-blood samples were collected, frozen and then shipped to the central laboratory for the measurement of glycated haemoglobin (HbA1c) by high-performance liquid chromatography using the VARIANT II Hemoglobin Testing System (BioRad Laboratories, Hercules, California). The eGFR was calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\textsuperscript{22}

2.3 | Definition

Overweight was defined by BMI ≥25 kg/m\textsuperscript{2}. Obesity was defined by BMI ≥30 kg/m\textsuperscript{2}. Elevated BP was defined by systolic BP/diastolic BP ≥140/90 mmHg. Diabetes was defined by fasting blood glucose
≥7.0 mmol/L and/or PBG ≥11.1 mmol/L and/or HbA1c ≥6.5%, and poor glycaemic control was defined by HbA1c ≥6.5%. High TG was defined by TG ≥1.70 mmol/L. Low HDL-c was defined by HDL-c <1.0 mmol/L for men or <1.3 mmol/L for women. Out of target for LDL-c was defined by LDL-c ≥2.6 mmol/L. Incident DKD was defined by an eGFR <60 mL/min/1.73 m² at the follow-up visit.

### 2.4 Statistical analysis

The continuous variables at baseline and follow-up visits are presented as means ± standard deviations (normal distribution) or medians (interquartile ranges) (skewed distribution). The categorical variables are presented as n (%). Skewed variables were logarithmically transformed before analysis. Differences between groups were analysed using the Student’s t-test for continuous variables and the chi-squared test for categorical variables. In addition, we used the Cohen’s d to estimate the standardized effect size for the comparisons of continuous variables between baseline and follow-up. A value of Cohen’s d between 0.20 and 0.49 is considered a small effect, 0.50-0.79 a medium effect, and ≥0.8 a large effect. Because the development of DKD was evaluated at the follow-up visit using eGFR levels, rather than collected during the entire follow-up period, and the proportional hazards assumption to Cox regression cannot be met, we used unadjusted and adjusted logistic regression models to examine the associations of metabolic abnormalities with DKD. Baseline eGFR was adjusted for the association between baseline metabolic abnormalities and DKD by including residual eGFR in the adjusted model to exclude the effect of multicollinearity. Based on Willett and Stampfer’s residual approach, we ran a single linear regression model in which the baseline eGFR was the dependent variable and all the other adjusted baseline variables were the independent variables. Ordinary least square residuals (i.e. ‘residual eGFR’) were then calculated by the actual eGFR minus predicted eGFR for each observation. The residual eGFR was the proportion of eGFR that was not related to the other adjusted variables in the model. The distributions of residual eGFR and actual eGFR are depicted in Supplementary Figure S1. We divided participants into four groups based on TG levels at baseline and follow-up: G1 (normal baseline TG and normal follow-up TG); G2 (high baseline TG and normal follow-up TG); G3 (normal baseline TG and high follow-up TG); and G4 (high baseline TG and high follow-up TG). The

| Characteristics | Baseline | Follow-up | p value | Cohen’s d |
|-----------------|----------|-----------|---------|-----------|
| Women (n, %)    | 6994 (62.8) | 6994 (62.8) | —       | —         |
| Age (years)     | 58.2 ± 8.3 | 61.4 ± 8.3 | <.001   | 0.39      |
| Current smoker (n, %) | 1655 (14.9) | 1753 (15.7) | <.001   | —         |
| BMI (kg/m²)     | 25.5 ± 3.5 | 25.2 ± 3.5 | <.001   | 0.09      |
| WC (cm)         | 86.9 ± 9.8 | 87.5 ± 10.0 | <.001   | 0.06      |
| SBP (mmHg)      | 137.0 ± 20.5 | 135.6 ± 19.3 | <.001   | 0.07      |
| DBP (mmHg)      | 80.4 ± 11.0 | 79.1 ± 11.2 | <.001   | 0.11      |
| FBG (mg/dL)     | 129.4 ± 38.7 | 125.8 ± 37.5 | <.001   | 0.09      |
| PBG (mg/dL)     | 223.2 ± 83.8 | 210.6 ± 84.1 | <.001   | 0.15      |
| HbA1c (%)       | 6.8 ± 1.3 | 6.5 ± 1.3 | <.001   | 0.24      |
| TG (mg/dL)      | 142.6 (99.2-209.0) | 141.7 (100.1-203.7) | .021    | 0.01      |
| LDL-c (mg/dL)   | 117.5 ± 35.6 | 123.3 ± 33.5 | <.001   | 0.17      |
| HDL-c (mg/dL)   | 50.2 ± 13.9 | 50.8 ± 11.9 | <.001   | 0.05      |
| Creatinine (mg/dL) | 0.8 ± 0.1 | 0.8 ± 0.2 | <.001   | 0.43      |
| eGFR (mL/min/1.73 m²) | 94.6 (85.8-100.9) | 87.2 (78.3-94.7) | <.001   | 0.58      |
| Overweight/obesity (n, %) | 6082 (54.6) | 5648 (50.7) | <.001   | —         |
| Elevated BP (n, %) | 4880 (43.8) | 4618 (41.4) | <.001   | —         |
| Poor glycaemic control (n, %) | 6730 (60.4) | 4090 (36.7) | <.001   | —         |
| High TG (n, %)  | 5126 (46.0) | 5059 (45.4) | <.001   | —         |
| Low HDL-c (n, %) | 4458 (40.0) | 4117 (37.0) | <.001   | —         |
| Out of target for LDL-c (n, %) | 7492 (67.2) | 8361 (75.0) | <.001   | —         |

Note: Overweight/obesity was defined by BMI ≥25 kg/m²; elevated BP was defined by systolic BP/diastolic BP ≥140/90 mmHg; diabetes was defined by FBG ≥7.0 mmol/L and/or PBG ≥11.1 mmol/L and/or HbA1c ≥6.5%; poor glycaemic control was defined by HbA1c ≥6.5%; high TG was defined by TG ≥1.70 mmol/L; low HDL-c was defined by HDL-c <1.0 mmol/L for men or <1.3 mmol/L for women; out of target for LDL-c was defined by LDL-c ≥2.6 mmol/L. TG and eGFR were presented as medians (interquartile ranges). Date are n(%), mean ± SD and median (range).

Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; PBG, post-load blood glucose; SBP, systolic blood pressure; TG, triglyceride; WC, waist circumference.
association of different TG groups with the risk of DKD was estimated using univariate and multivariate logistic regression analysis. Factors associated with persistently high TG were examined using multivariate logistic regression analysis. \( p < .05 \) was considered statistically significant. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

| Characteristics                  | Without incident DKD (N = 10 789) | With incident DKD (N = 353) | \( p \) value |
|----------------------------------|----------------------------------|-----------------------------|----------------|
| Women (n, %)                     | Baseline 6794 (63.0)             | 200 (56.7)                  | .016           |
| Age (years)                      | Baseline 57.9 ± 8.1               | 66.7 ± 8.3                  | <.001          |
| Current smoker (n, %)            | Baseline 1610 (14.9)              | 45 (12.8)                   | .379           |
| Follow-up                        | 1705 (15.8)                      | 48 (13.6)                   | .478           |
| BMI (kg/m²)                      | Baseline 25.5 ± 3.5               | 25.5 ± 3.4                  | .877           |
| Follow-up                        | 25.2 ± 3.5                       | 25.3 ± 3.4                  | .791           |
| WC (cm)                          | Baseline 86.8 ± 9.8               | 88.9 ± 9.2                  | <.001          |
| Follow-up                        | 87.4 ± 10.0                      | 89.3 ± 9.4                  | <.001          |
| SBP (mmHg)                       | Baseline 136.7 ± 20.5             | 144.1 ± 21.4                | <.001          |
| Follow-up                        | 135.4 ± 19.2                     | 140.7 ± 21.0                | <.001          |
| DBP (mmHg)                       | Baseline 80.3 ± 10.9              | 81.1 ± 12.4                 | .194           |
| Follow-up                        | 79.1 ± 11.1                      | 78.8 ± 12.2                 | .591           |
| FBG (mg/dL)                      | Baseline 129.5 ± 38.7             | 128.0 ± 38.8                | .489           |
| Follow-up                        | 125.7 ± 37.4                     | 128.4 ± 41.7                | .187           |
| PBG (mg/dL)                      | Baseline 223.2 ± 83.7             | 223.2 ± 85.6                | .990           |
| Follow-up                        | 210.2 ± 83.6                     | 225.1 ± 97.4                | .001           |
| HbA1c (%)                        | Baseline 6.8 ± 1.3                 | 6.8 ± 1.4                   | .819           |
| Follow-up                        | 6.5 ± 1.2                        | 6.6 ± 1.3                   | .062           |
| TG (mg/dL)                       | Baseline 141.7 (99.2-209.9)       | 148.8 (108.9-204.6)         | .328           |
| Follow-up                        | 141.7 (100.1-202.8)              | 155.0 (116.9-220.5)         | <.001          |
| LDL-C (mg/dL)                    | Baseline 117.5 ± 35.5             | 117.6 ± 39.4                | .942           |
| Follow-up                        | 123.2 ± 33.3                     | 124.7 ± 39.5                | .408           |
| HDL-C (mg/dL)                    | Baseline 50.2 ± 13.9              | 48.3 ± 14.1                 | .011           |
| Follow-up                        | 50.9 ± 11.9                      | 48.2 ± 11.0                 | <.001          |
| Creatinine (mg/dL)               | Baseline 0.8 ± 0.1                 | 0.9 ± 0.2                   | <.001          |
| Follow-up                        | 0.8 ± 0.1                        | 1.2 ± 0.4                   | <.001          |
| eGFR (mL/min/1.73 m²)            | Baseline 94.9 (86.6-101.1)        | 73.1 (65.6-83.2)            | <.001          |
| Follow-up                        | 87.7 (79.3-94.9)                 | 54.6 (50.1-57.8)            | <.001          |
| Overweight/obesity (n, %)        | Baseline 5891 (54.6)              | 191 (54.1)                  | .854           |
| Follow-up                        | 5469 (50.7)                      | 179 (50.7)                  | .995           |
| Elevated BP (n, %)               | Baseline 4684 (43.4)              | 196 (55.5)                  | <.001          |
| Follow-up                        | 4441 (41.2)                      | 177 (50.1)                  | <.001          |
| Poor glycaemic control (n, %)    | Baseline 6515 (60.4)              | 215 (60.9)                  | .844           |
| Follow-up                        | 3948 (36.6)                      | 142 (40.2)                  | .163           |
| High TG (n, %)                   | Baseline 4950 (45.9)              | 176 (49.9)                  | .140           |
| Follow-up                        | 4871 (45.1)                      | 188 (53.3)                  | .003           |
| Low HDL-c (n, %)                 | Baseline 4301 (39.9)              | 157 (44.5)                  | 0.082          |
| Follow-up                        | 3979 (36.9)                      | 138 (39.1)                  | .397           |
| Out of target for LDL-c (n, %)   | Baseline 7256 (67.3)              | 236 (66.9)                  | .875           |
| Follow-up                        | 8104 (75.1)                      | 257 (72.8)                  | .324           |

Note: Date are n(%), mean ± SD and median (range). Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; PBG, post-load blood glucose; SBP, systolic blood pressure; TG, triglyceride; WC, waist circumference.
3 | RESULTS

3.1 | Baseline and follow-up characteristics of study participants

The demographics and laboratory results of study participants are shown in Table 1. All characteristics were compared between baseline and follow-up visits. Although characteristics at the follow-up visit showed lower levels of BMI, BP, blood glucose and TG, and higher levels of HDL-c, the proportions of various metabolic abnormalities were also very high. Besides, waist circumference and LDL-c levels increased during follow-up and eGFR decreased on average from 94.6 to 87.2 mL/min/1.73 m². However, the Cohen’s d revealed that most changes between baseline and follow-up were small.

3.2 | Characteristics of study participants by diabetic kidney disease status

To explore the possible related factors of DKD occurrence in new-onset type 2 diabetes, we divided study participants into two groups based on the DKD status at follow-up. As shown in Table 2, participants with incident DKD were probably not female and were older in age, had higher levels of waist circumference and systolic BP, and lower levels of HDL-c at both baseline and follow-up. In addition, although the baseline levels of PBG and TG were not significantly different between groups, participants with incident DKD presented higher levels of PBG and TG at follow-up.

3.3 | Associations of baseline and follow-up metabolic abnormalities with diabetic kidney disease

The associations of baseline and follow-up metabolic abnormalities with risks of incident DKD are shown in Table 3. At baseline, high TG [odds ratio (OR) = 1.37, 95% confidence interval (CI) = 1.07-1.74] was significantly associated with an increased risk of DKD after adjustment for covariates (age, gender, education, physical activity, current drinking status, current smoking status, overweight/obesity, elevated BP, poor glycaemic control, high TG, low HDL-c, out of target for LDL-c and residual eGFR at baseline). The association between baseline low HDL-c and DKD was borderline significant (OR = 1.30, TABLE 3 Associations of baseline and follow-up metabolic abnormalities with risks of incident diabetic kidney disease

| Variables | Unadjusted | Model 1 |
|-----------|------------|---------|
| Baseline analysis | | |
| Age (per year) | 1.14 (1.12-1.16) | <.001 | 1.17 (1.16-1.19) | <.001 |
| Sex (women vs. men) | 0.77 (0.62-0.95) | .016 | 0.96 (0.73-1.28) | .796 |
| Current smoking | 0.82 (0.60-1.13) | .635 | 1.15 (0.78-1.71) | .467 |
| Overweight/obesity | 0.98 (0.79-1.21) | .854 | 0.99 (0.78-1.26) | .952 |
| Elevated BP | 1.63 (1.31-2.01) | <.001 | 1.19 (0.93-1.51) | .164 |
| Poor glycaemic control | 1.02 (0.82-1.27) | .844 | 0.99 (0.78-1.26) | .949 |
| High TG | 1.17 (0.95-1.45) | .140 | 1.37 (1.07-1.74) | .012 |
| Low HDL-c | 1.21 (0.98-1.50) | .082 | 1.30 (0.99-1.70) | .057 |
| Out of target for LDL-c | 0.98 (0.78-1.23) | .875 | 1.12 (0.86-1.46) | .412 |
| Follow-up analysis | | |
| Age (per year) | 1.14 (1.12-1.16) | <.001 | 1.14 (1.13-1.16) | <.001 |
| Sex (women vs. men) | 0.77 (0.62-0.95) | .016 | 0.80 (0.63-1.02) | .074 |
| Current smoking | 0.85 (0.62-1.16) | .226 | 1.11 (0.77-1.60) | .754 |
| Overweight/obesity | 1.00 (0.81-1.24) | .995 | 1.01 (0.81-1.27) | .922 |
| Elevated BP | 1.44 (1.16-1.78) | <.001 | 1.05 (0.84-1.30) | .693 |
| Poor glycaemic control | 1.17 (0.94-1.45) | .164 | 1.16 (0.93-1.46) | .193 |
| High TG | 1.38 (1.12-1.71) | .003 | 1.71 (1.35-2.16) | <.001 |
| Low HDL-c | 1.10 (0.88-1.37) | .397 | 1.10 (0.85-1.41) | .480 |
| Out of target for LDL-c | 0.89 (0.70-1.13) | .324 | 0.94 (0.73-1.21) | .625 |

Note: For the baseline analysis, model 1 was adjusted for education, physical activity at baseline, current drinking status at baseline, residual estimated glomerular filtration rate at baseline, and all other baseline variables in the table. For follow-up analysis, model 1 was adjusted for education, physical activity at follow-up, current drinking status at follow-up and all other follow-up variables in the table. Significant P values (<0.05) are indicated in bold.

Abbreviations: BP, blood pressure; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TG, triglyceride.
 Associations of high triglyceride at baseline or at follow-up with risks of incident diabetic kidney disease

| Variables | No. of cases/no. of participants (%) | Unadjusted | Model 1 | Model 2 |
|-----------|-------------------------------------|------------|---------|---------|
| High TG   |                                     |            |         |         |
| G1        | 122/4565 (2.67)                     | 1.00       | 1.00    | 1.00    |
| G2        | 43/1518 (2.83)                      | 1.06 (0.75-1.51) | 1.21 (0.84-1.74) | 1.13 (0.77-1.68) |
| G3        | 55/1451 (3.79)                      | 1.43 (1.04-1.98) | 1.81 (1.29-2.53) | 1.77 (1.23-2.55) |
| G4        | 133/3608 (3.69)                     | 1.39 (1.09-1.79) | 1.90 (1.46-2.47) | 1.65 (1.23-2.22) |

Note: G1, normal baseline TG and normal follow-up TG; G2, high baseline TG and normal follow-up TG; G3, normal baseline TG and high follow-up TG; G4, high baseline TG and high follow-up TG. Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, education, physical activity, current smoking status, current drinking status, body mass index, systolic blood pressure, diastolic blood pressure, glycated haemoglobin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and residual estimated glomerular filtration rate. All the adjusted variables were from the baseline visit. Significant P values (<0.05) are indicated in bold.

95% CI = 0.99-1.70). However, at follow-up, only high TG was found to be significantly correlated with increased risks of DKD (OR = 1.71, 95% CI = 1.35-2.16). The associations of baseline and changes of lipids during follow-up with annual reductions in eGFR are shown in the Supplementary Table S1.

3.4 Associations of different triglyceride control status with diabetic kidney disease

The associations of the four TG groups with risks of incident DKD are presented in Table 4. For patients with high TG levels at baseline, the risk of DKD did not increase by tight control of TG (OR = 1.13, 95% CI = 0.77-1.68). Patients with high TG levels at follow-up or at both baseline and follow-up had significantly increased risks of DKD compared with constantly normal TG (OR = 1.77, 95% CI = 1.23-2.55 for elevated TG at follow-up; OR = 1.65, 95% CI = 1.23-2.22 for persistently elevated TG) after adjustment for covariates (age, sex, education, physical activity, current smoking status, current drinking status, BMI, systolic BP, diastolic BP, HbA1c, HDL-c, LDL-c and residual eGFR at baseline). Men and women were not significantly different in the association between TG groups and DKD (Supplementary Table S2). Examination of factors associated with persistently high TG revealed that age, gender, overweight/obesity, elevated BP, low HDL and high LDL were all significantly associated (Supplementary Table S3).

4 DISCUSSION

Using data from a large, nationwide, multicentre, prospective cohort study of Chinese adults ≥40 years, we found that among many metabolic abnormalities such as overweight/obesity, elevated BP, poor glycaemic control and dyslipidaemia, high TG was significantly associated with the development of DKD in patients with new-onset diabetes. In addition, participants with good control of high TG during follow-up might have a reduced risk of DKD compared with those without. Therefore, long-term TG control may be very important for the prevention of DKD in diabetic patients in China, which remains to be tested in more randomized trials.

DKD is a major microvascular complication of type 2 diabetes, which is the leading cause of end-stage renal disease, accounting for nearly half of all patients receiving renal replacement therapy and is associated with cardiovascular disease and high public health care costs.25,26 Studies of both patients with type 1 diabetes and patients with type 2 diabetes indicate that intensive glycaemic control can reduce the incidence and progression of DKD. Overall, results of interventional studies have suggested that glucose plays only a partial role in the development of renal damage, and that a range of factors, including hypertension and dyslipidaemia, may play important roles in the development and progression of DKD.27-29 Elevated BP was significantly associated with DKD in univariate analysis in the current study. However, adjustment for age attenuated the association towards null. Many patients with diabetes meet the recommended targets for blood glucose and BP control, but the residual risk of DKD remains high. Therefore, in addition to hyperglycaemia and hypertension, the identification of other modifiable risk factors is needed. A recent systematic review and meta-analysis showed that age, smoking and TG were the most powerful baseline risk factors for detecting DKD.30

In our study, both high TG and low HDL-c at baseline were significantly or borderline significantly associated with increased risk of DKD. Previous studies have shown that high TG and low HDL-c levels play a crucial role in the development and progression of DKD.5,31 However, at follow-up, only high TG was significantly correlated with the occurrence of DKD. A cross-sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study also found significant associations of high TG with chronic kidney disease in subjects with type 2 diabetes.32 However, there are also studies that have suggested that only HDL-c levels but not TG levels are associated with the progression of DKD.16 There are conflicting study results in the literature about TG levels in DKD in type 2 diabetes. While elevated TG levels have been reported in patients with diabetes with kidney disease,6 other reports found no difference in TG levels between diabetic subjects with and without diabetic kidney injury.5 These differences may be related to race, gender and genetic
background of study participants. Intervventional studies reducing TG levels have provided additional evidence. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study is a multinational randomized controlled trial involving 9795 patients with type 2 diabetes. After 4 months of treatment, the fenofibrate group significantly reduced the rate of proteinuria progression compared with the placebo group. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, incidence of both microalbuminuria and macroalbuminuria was lower in the fenofibrate group than in the placebo group.

The underlying mechanism of renal dysfunction caused by dyslipidaemia remains unclear. Lipids may accumulate in renal tissue due to an imbalance of synthesis, uptake or outflow. Lipid deposition may lead to damage of mesangial cells, endothelial cells and podocytes by inducing inflammatory response, increasing oxidative stress and promoting the release of growth factors, leading to glomerulosclerosis and tubular damage. The kidney is negatively affected by dyslipidaemia and lipid accumulation that bring about alterations in renal lipid metabolism. Besides, hyperglycaemia in diabetes promotes lipid toxicity and is necessary for the development of DKD. AMP-activated protein kinase, sterol regulatory element binding protein-1 and some metabolic hormone receptors, including liver X receptors, farnesoid X receptors and peroxisome proliferator-activated receptors regulate the crosstalk of hyperglycaemia and dyslipidaemia in DKD. Hyperglycaemia can cause dysregulation of polyl and hexosamine fluxes, advanced glycation end-products and activation of protein kinase C isoforms. High-fat diet has been shown to aggravate proteinuria and glomerulopathy in diabetic mice, suggesting a synergistic effect of lipid and glucose on renal damage.

In our study, overweight/obesity, elevated BP, poor glycaemic control were not significantly associated with the risks of DKD development. Fourth, metabolic factors during follow-up. However, control of metabolic abnormalities at follow-up and incident DKD were examined at the same time, thus the association at follow-up was essentially a cross-sectional analysis. A second follow-up is desirable to examine the development of DKD after evaluation of metabolic control.

ACKNOWLEDGMENTS
This work was supported by the National Key R&D Program of China (2018YFC1311801), the National Natural Science Foundation of China (grant numbers: 81400814, 81873632, 81770818 and 81400769), the Cheeloo College of Medicine, Shandong University Graduate Education Innovation Plan (2020Y11) and the Ministry of Science and Technology of the People’s Republic of China (grant numbers: 2016YFC1305600, 2016YFC1305202, 2016YFC1304904, 2017YFC1310700, 2018YFC1311705 and 2018YFC1311800).

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
Li Chen and Xinguo Hou designed the study. Guang Ning, Weiqing Wang, Gang Chen, Qin Wan, Guijun Qin, Li Yan, Guixia Wang, Yingfen Qin, Zuojie Luo, Xulei Tang, Yanan Huo, Ruying Hu, Zhen Ye, Lixin Shi, Zhengnan Gao, Qing Su, Yiming Mu, Jiajun Zhao, Lulu Chen, Tiange Wang, Zhiyun Zhao, Lei Gong and Chuan Wang collected the epidemiological and clinical data. Lei Gong and Chuan Wang analysed data. Lei Gong and Chuan Wang drafted the manuscript. Li Chen and Xinguo Hou revised the final manuscript. All authors approved the final version.

DATA AVAILABILITY STATEMENT
The dataset generated during the current study is available from the corresponding author on reasonable request.

ORCID
Gang Chen https://orcid.org/0000-0002-8105-2384
Guijun Qin https://orcid.org/0000-0002-2503-7534
16. Hanai K, Babazono T, Yoshida N, et al. Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients. Nephrol Dial Transplant. 2012;27(3):1070-1075.

17. Tu ST, Chang SJ, Chen JF, et al. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus: a 4-year prospective analysis. Arch Intern Med. 2010;170(2):155-161.

18. Retnakaran R, Cull CA, Thorne KL, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55(6):1832-1839.

19. Wang T, Lu J, Su Q, et al. Ideal cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol. 2019;4(9):874-883.

20. Lu J, He J, Li M, et al. Predictive value of fasting glucose, postload glucose, and hemoglobin A1c on risk of diabetes and complications in Chinese adults. Diabetes Care. 2019;42(8):1539-1548.

21. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes. 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2020;43(2):487-493.

22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.

23. Algina J, Keselman HJ, Penfield RD. An alternative to Cohen's standardized mean difference effect size: a robust parameter and confidence interval in the two independent groups case. Psychol Methods. 2005;10(3):317-328.

24. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol. 1986;124(1):17-27.

25. Saran R, Robinson B, Abbott KC, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(1 suppl 1):A6-A7.

26. Li H, Lu W, Wang A, Jiang H, Luy J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from global burden of disease 2017. J Diabetes Investig. 2021;12(3):346-356.

27. Nathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16.

28. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.

29. Duckworth W, Abrâira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.

30. Jiang W, Wang J, Shen X, et al. Establishment and validation of a risk prediction model for early diabetic kidney Disease based on a systematic review and meta-analysis of 20 cohorts. Diabetes Care. 2020;43(4):925-933.

31. Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):1009-1008.

32. Penno G, Solini A, Zoppini G, et al. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. PLoS One. 2015;10(5):e0125512.

33. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.

34. Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.

35. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002;277(21):18919-18927.
36. Zager RA, Johnson A. Renal cortical cholesterol accumulation is an integral component of the systemic stress response. *Kidney Int*. 2001; 60(6):2299-2310.

37. Ducasa GM, Mitrofanova A, Fornoni A. Crosstalk between lipids and mitochondria in diabetic kidney disease. *Curr Diab Rep*. 2019; 19(12):144.

38. Russo G, Piscitelli P, Giandalia A, et al. Atherogenic dyslipidemia and diabetic nephropathy. *J Nephrol*. 2020;33(5):1001-1008.

39. Izquierdo-Lahuerta A, Martinez-Garcia C, Medina-Gomez G. Lipotoxicity as a trigger factor of renal disease. *J Nephrol*. 2016;29(5):603-610.

40. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. *Nat Clin Pract Endocrinol Metab*. 2008;4(8):444-452.

41. Su W, Cao R, He YC, Guan YF, Ruan XZ. Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney Disease. *Kidney Dis*. 2017;3(4):171-180.

42. Kuwabara T, Mori K, Mukoyama M, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by toll-like receptor 4 in mice. *Diabetologia*. 2012;55(8):2256-2266.

43. Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. *Clin Exp Nephrol*. 2014;18(2):206-209.

44. Ogna A, Formi Ogna V, Bochud M, et al. Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. *Eur J Nutr*. 2016;55(3):1089-1097.

45. Palatini P, Dorigatti F, Saladini F, et al. Factors associated with glomerular hyperfiltration in the early stage of hypertension. *Am J Hypertens*. 2012;25(9):1011-1016.

46. Hou X, Wang C, Wang S, et al. Fluctuation between fasting and 2-H postload glucose state is associated with glomerular hyperfiltration in newly diagnosed diabetes patients with HbA1c < 7%. *PLoS One*. 2014;9(10):e111173.

47. de Boer IH, Caramori ML, Chan JC, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int*. 2020;98(4S):S1-S115.

48. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111-188.

49. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). *Chin J Diabetes Mellitus*. 2021;13(4):317-411.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Gong L, Wang C, Ning G, et al. High concentrations of triglycerides are associated with diabetic kidney disease in new-onset type 2 diabetes in China: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study. *Diabetes Obes Metab*. 2021;23(11):2551-2560. [https://doi.org/10.1111/dom.14502](https://doi.org/10.1111/dom.14502)